Trial · NCT05895838
Registered outcomes31
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 31
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Steroid intervention primary endpoint: All-cause mortality | 90 days | Number of patients dying from all causes |
| Primary | Back rest position intervention primary endpoint: All-cause mortality | 90 days | Number of patients dying from all causes |
| Primary | Early wakeup and extubation intervention primary endpoint: Days alive outside hospital | 30 days | Counted as days alive outside of hospital after discharge |
| Primary | Olanzapine intervention primary endpoint: Days alive outside hospital | 30 days | Counted as days alive outside of hospital after discharge |
| Secondary | Steroid intervention: Number of patients with one or more serious adverse reactions to dexamethasone in the ICU | Patients will be monitored for the occurrence of an adverse event for 30 days after randomization or until hospital discharge if this occurs later than 30 days and will not be followed for adverse event reporting after this. | Number of patients with one or more serious adverse reactions to dexamethasone in the ICU |
| Secondary | Steroid intervention: Days alive outside hospital within 30 days | 30 days | Days alive outside hospital within 30 days |
| Secondary | Steroid intervention: Cerebral Performance Category (CPC) and Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest | 3-6 months | Cerebral Performance Category (CPC) and Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest (conducted either through physical attendance or telephone interview according to participant preference) |
| Secondary | Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest | 3-6 months | Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest (conducted either through physical attendance or telephone interview according to participant preference) |
| Secondary | Steorid intervention: Serum Neuron Specific Enolase (NSE) at 48-72 hours | 48-72 hours | Serum Neuron Specific Enolase (NSE) at 48-72 hours |
| Secondary | Steroid intervention: Markers of inflammation (high-sensitivity C reactive protein) | 0-72 hours | Markers of inflammation; high-sensitivity C reactive protein. platelet-, leukocyte- and differential count daily during the initial 72 hours |
| Secondary | Steroid intervention: Markers of inflammation (platelet count) | 0-72 hours | Markers of inflammation; high-sensitivity C reactive protein. platelet-, leukocyte- and differential count daily during the initial 72 hours |
| Secondary | Steroid intervention: Markers of inflammation (leukocyte- and differential count) | 0-72 hours | Markers of inflammation; high-sensitivity C reactive protein. platelet-, leukocyte- and differential count daily during the initial 72 hours |
| Secondary | Backrest position intervention: Serum Neuron Specific Enolase (NSE) at 48 hours at sites where this is in routine use. | 48 hours | Serum Neuron Specific Enolase (NSE) at 48 hours at sites where this is in routine use. |
| Secondary | Backrest position intervention: Duration of intubation (oral and tracheostomy combined) | During the index hospital admission, assessed up to 1 year after randomization | Duration of intubation (oral and tracheostomy combined) |
| Secondary | Backrest position intervention: ICU length of stay | During the index hospital admission, assessed up to 1 year after randomization | ICU length of stay |
| Secondary | Backrest position intervention: Days alive outside hospital within 30 days | 30 days | Days alive outside hospital within 30 days |
| Secondary | Backrest position intervention: Hospital length of stay | During the index hospital admission, assessed up to 1 year after randomization. | Backrest position intervention: Hospital length of stay (including in-patient rehabilitation and transfer to referral hospital) |
| Secondary | Backrest position intervention: Cerebral Performance Category (CPC) at 3-6 months follow-up. | 3-6 months | Cerebral Performance Category (CPC) and the modified Rankin Scale (mRS) at 3-6 months follow-up (conducted either through physical attendance or telephone interview according to participant preference). |
| Secondary | Backrest position intervention: The modified Rankin Scale (mRS) at 3-6 months follow-up. | 3-6 months | Cerebral Performance Category (CPC) and the modified Rankin Scale (mRS) at 3-6 months follow-up (conducted either through physical attendance or telephone interview according to participant preference). |
| Secondary | Early wakeup and extubation intervention: All-cause mortality at 90 days. | 90 days | All-cause mortality at 90 days |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05895838/registered